134 related articles for article (PubMed ID: 15115390)
1. Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis.
Becker JW; Rotonda J; Soisson SM; Aspiotis R; Bayly C; Francoeur S; Gallant M; Garcia-Calvo M; Giroux A; Grimm E; Han Y; McKay D; Nicholson DW; Peterson E; Renaud J; Roy S; Thornberry N; Zamboni R
J Med Chem; 2004 May; 47(10):2466-74. PubMed ID: 15115390
[TBL] [Abstract][Full Text] [Related]
2. Structural and kinetic analysis of caspase-3 reveals role for s5 binding site in substrate recognition.
Fang B; Boross PI; Tozser J; Weber IT
J Mol Biol; 2006 Jul; 360(3):654-66. PubMed ID: 16781734
[TBL] [Abstract][Full Text] [Related]
3. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
[TBL] [Abstract][Full Text] [Related]
4. Conformational restrictions in the active site of unliganded human caspase-3.
Ni CZ; Li C; Wu JC; Spada AP; Ely KR
J Mol Recognit; 2003; 16(3):121-4. PubMed ID: 12833566
[TBL] [Abstract][Full Text] [Related]
5. Using peptidic inhibitors to systematically probe the S1' site of caspase-3 and caspase-7.
Goode DR; Sharma AK; Hergenrother PJ
Org Lett; 2005 Aug; 7(16):3529-32. PubMed ID: 16048334
[TBL] [Abstract][Full Text] [Related]
6. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors.
Ganesan R; Jelakovic S; Campbell AJ; Li ZZ; Asgian JL; Powers JC; Grütter MG
Biochemistry; 2006 Aug; 45(30):9059-67. PubMed ID: 16866351
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10.
Ekici OD; Li ZZ; Campbell AJ; James KE; Asgian JL; Mikolajczyk J; Salvesen GS; Ganesan R; Jelakovic S; Grütter MG; Powers JC
J Med Chem; 2006 Sep; 49(19):5728-49. PubMed ID: 16970398
[TBL] [Abstract][Full Text] [Related]
8. Caspase-8 specificity probed at subsite S(4): crystal structure of the caspase-8-Z-DEVD-cho complex.
Blanchard H; Donepudi M; Tschopp M; Kodandapani L; Wu JC; Grütter MG
J Mol Biol; 2000 Sep; 302(1):9-16. PubMed ID: 10964557
[TBL] [Abstract][Full Text] [Related]
9. Caspase-3 binds diverse P4 residues in peptides as revealed by crystallography and structural modeling.
Fang B; Fu G; Agniswamy J; Harrison RW; Weber IT
Apoptosis; 2009 May; 14(5):741-52. PubMed ID: 19283487
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional analysis of caspase active sites.
Chéreau D; Kodandapani L; Tomaselli KJ; Spada AP; Wu JC
Biochemistry; 2003 Apr; 42(14):4151-60. PubMed ID: 12680769
[TBL] [Abstract][Full Text] [Related]
11. Conformational similarity in the activation of caspase-3 and -7 revealed by the unliganded and inhibited structures of caspase-7.
Agniswamy J; Fang B; Weber IT
Apoptosis; 2009 Oct; 14(10):1135-44. PubMed ID: 19655253
[TBL] [Abstract][Full Text] [Related]
12. Plasticity of S2-S4 specificity pockets of executioner caspase-7 revealed by structural and kinetic analysis.
Agniswamy J; Fang B; Weber IT
FEBS J; 2007 Sep; 274(18):4752-65. PubMed ID: 17697120
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8.
James KE; Asgian JL; Li ZZ; Ekici OD; Rubin JR; Mikolajczyk J; Salvesen GS; Powers JC
J Med Chem; 2004 Mar; 47(6):1553-74. PubMed ID: 14998341
[TBL] [Abstract][Full Text] [Related]
15. Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex.
Xu G; Cirilli M; Huang Y; Rich RL; Myszka DG; Wu H
Nature; 2001 Mar; 410(6827):494-7. PubMed ID: 11260720
[TBL] [Abstract][Full Text] [Related]
16. In situ assembly of enzyme inhibitors using extended tethering.
Erlanson DA; Lam JW; Wiesmann C; Luong TN; Simmons RL; DeLano WL; Choong IC; Burdett MT; Flanagan WM; Lee D; Gordon EM; O'Brien T
Nat Biotechnol; 2003 Mar; 21(3):308-14. PubMed ID: 12563278
[TBL] [Abstract][Full Text] [Related]
17. Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity.
Pereira NA; Song Z
Biochem Biophys Res Commun; 2008 Dec; 377(3):873-7. PubMed ID: 18976637
[TBL] [Abstract][Full Text] [Related]
18. Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis.
Ganesan R; Mittl PR; Jelakovic S; Grütter MG
J Mol Biol; 2006 Jun; 359(5):1378-88. PubMed ID: 16787777
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P(2) amino acid by 2-aminoaryl acids and other non-natural amino acids.
Wang Y; Jia S; Tseng B; Drewe J; Cai SX
Bioorg Med Chem Lett; 2007 Nov; 17(22):6178-82. PubMed ID: 17889532
[TBL] [Abstract][Full Text] [Related]
20. N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies.
Chu W; Zhang J; Zeng C; Rothfuss J; Tu Z; Chu Y; Reichert DE; Welch MJ; Mach RH
J Med Chem; 2005 Dec; 48(24):7637-47. PubMed ID: 16302804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
